STOCK TITAN

IGC Pharma (IGC) Financials

IGC NYSE
FY2025 annual
Revenue $1.3M -5.5% YoY
Net Income -$7.1M n/m YoY
EPS (Diluted) -$0.09 n/m YoY
Free Cash Flow -$4.9M n/m YoY
Market Cap $19.6M as of Nov 20, 2026
Price / Sales 15.4x on $1.3M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 3.0x on $6.5M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE March

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IGC SEC filings page.

IGC Pharma, Inc. (IGC) reported $1.3M in revenue for fiscal year 2025, down 5.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IGC FY2025

IGC remains a development-stage business: revenue is small relative to R&D, and recurring losses are financed largely through new capital.

In FY2025, revenue was $1.27M while R&D alone was $3.66M; the business is spending several times its sales on development. Because operating cash flow was negative while financing cash flow was positive, reported activity depended on external funding rather than internally generated cash.

SG&A fell from $6.76M in FY2024 to $4.41M in FY2025, indicating deliberate overhead reduction. Yet gross margin narrowed from 54.5% to 48.7%, so lower overhead has not translated into better product-level economics.

The supplied liquidity measure equals 1 month of reported annual outflow, pointing to limited near-term financial flexibility. Meanwhile, current ratio fell from 3.4x in FY2023 to 1.3x in FY2025, tightening the cushion for paying near-term obligations.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 44 / 100
Financial Health Score 44/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of IGC Pharma, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
5

IGC Pharma, Inc. held $405K in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $4.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and IGC Pharma, Inc. scores 5/100 among other emerging companies.

Dilution
34

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. IGC Pharma, Inc. scores 34/100 on it among other emerging companies.

R&D Intensity
72

IGC Pharma, Inc. spent $3.7M on research and development in fiscal year 2025, which was 41.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and IGC Pharma, Inc. scores 72/100 among other emerging companies.

Revenue Progress
61

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. IGC Pharma, Inc. scores 61/100 on it among other emerging companies.

Burn Trend
65

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. IGC Pharma, Inc. scores 65/100 on it among other emerging companies.

Balance Sheet
24

IGC Pharma, Inc.'s cash, cash equivalents and investments came to $405K at the end of fiscal year 2025, against $2.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and IGC Pharma, Inc. scores 24/100 among other emerging companies.

Altman Z-Score Distress
-17.04

IGC Pharma, Inc. scores -17.04, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $120.7M against total assets of $8.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak
3/9

IGC Pharma, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

IGC Pharma, Inc. reported a net loss of $7.1M while operations used $4.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

IGC Pharma, Inc. reported an operating loss of $7.4M against $5K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$328K
YoY+27.6%
QoQ+23.8%

IGC Pharma, Inc. generated $328K in revenue in Q3 2026. This represents an increase of 27.6% from the same quarter a year earlier. Against the prior quarter it is up 23.8%.

EBITDA
-$1.9M
YoYn/m
QoQn/m

IGC Pharma, Inc.'s EBITDA was -$1.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$2.0M
YoYn/m
QoQn/m

IGC Pharma, Inc. reported a net loss of $2.0M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.02
YoYn/m
QoQn/m

IGC Pharma, Inc. earned -$0.02 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$1.4M
YoYn/m
QoQn/m

IGC Pharma, Inc. recorded an outflow of $1.4M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$377K
YoY-19.8%
QoQ+13.9%
5Y CAGR-51.7%
10Y CAGR-8.7%

IGC Pharma, Inc. held $377K in cash against $128K in long-term debt as of Q3 2026, with $3.1M of liabilities due within a year.

Shares Outstanding
117M
YoY+46.4%
QoQ+12.9%
5Y CAGR+18.0%
10Y CAGR+15.2%

IGC Pharma, Inc. had 117M shares outstanding in Q3 2026. This represents an increase of 46.4% from the same quarter a year earlier. Against the prior quarter it is up 12.9%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
18.6%
YoY-21.9pp
QoQ+0.5pp

IGC Pharma, Inc.'s gross margin was 18.6% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 21.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.

Return on Equity
-31.5%
YoY-2.2pp
QoQ+16.4pp

IGC Pharma, Inc.'s quarterly ROE was -31.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 16.4 percentage points.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$1.0M
YoY+18.9%
QoQ-27.1%

IGC Pharma, Inc. invested $1.0M in research and development in Q3 2026. This represents an increase of 18.9% from the same quarter a year earlier. Against the prior quarter it is down 27.1%.

Capital Expenditures
$0
YoY-100.0%
QoQ-100.0%

IGC Pharma, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

IGC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IGC quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KTQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-Q
Revenue$328K+27.6%$265K-35.7%$317K+16.5%N/A$191K-53.6%$328K+20.6%$330K+11.9%$257K+26.0%
Cost of Revenue$267K+74.5%$217K+1.4%$262K+140.4%N/A$92K-57.0%$174K+59.6%$176K+41.9%$153K+115.5%
Gross Profit$61K-41.3%$48K-75.8%$55K-66.3%N/A$99K-50.0%$154K-5.5%$154K-9.9%$104K-21.8%
R&D Expenses$1.0M+18.9%$1.4M+51.6%$1.3M+43.1%N/A$1.6M+73.2%$851K-4.3%$997K+16.6%$852K-5.6%
SG&A Expenses$979K-13.4%$1.4M+38.5%$1.2M-25.7%N/A$1.4M+35.4%$1.2M-27.7%$570K-61.6%$1.1M-49.3%
Operating Income-$1.9Mn/m-$2.8Mn/m-$2.5Mn/mN/A-$2.9Mn/m-$1.9Mn/m-$1.4Mn/m-$1.9Mn/m
EBITDA-$1.9Mn/m-$2.7Mn/m-$2.4Mn/mN/A-$2.8Mn/m-$1.8Mn/m-$1.3Mn/m-$1.7Mn/m
Interest ExpenseN/AN/A$1K0.0%N/AN/A$1K0.0%N/AN/A
Income Tax$0n/m$0n/m$0n/mN/A$0n/m$0n/m$0n/m$0n/m
Net Income-$2.0Mn/m-$2.9Mn/m-$2.4Mn/mN/A-$1.8Mn/m-$1.6Mn/m-$1.2Mn/m-$1.8Mn/m
EPS (Basic)-$0.02n/m-$0.03n/m-$0.02n/mN/A-$0.02n/m-$0.02n/m-$0.02n/m-$0.02n/m
EPS (Diluted)-$0.02n/m-$0.03n/m-$0.02n/mN/A-$0.02n/m-$0.02n/m-$0.02n/m-$0.02n/m
Diluted Shares (Avg)109M+41.0%100M+32.0%98M+34.8%N/A90M+19.0%83M+14.0%80M78M+21.8%

IGC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IGC quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KTQ2'2610-QQ1'2610-QQ4'2510-KTQ3'2510-Q
Total Assets$9.7M+7.2%$9.5M-8.4%$9.2M-13.3%$9.7M-1.9%$9.7M-6.0%$7.9M-25.0%$8.7M-11.7%$9.1M-19.4%
Current Assets$1.3M-57.2%$1.3M-70.3%$1.1M-74.0%$1.8M-51.7%$2.0M-52.8%$2.2M-51.1%$2.9M-21.8%$3.1M-14.8%
Cash & Equivalents$377K-19.8%$331K-78.6%$207K-88.7%$900K-24.9%$1.1M-28.5%$454K-75.1%$405K-66.2%$470K-65.9%
Short-Term Investments$36Kn/m$23Kn/m$28Kn/m$38Kn/m$25Kn/m$0n/m$0n/m$0n/m
Inventory$643K-55.1%$640K-57.6%$638K-57.7%$640K-58.4%$658K-56.4%$1.3M-10.7%$1.4M-11.7%$1.4M-25.6%
Accounts Receivable$68K+38.8%$56K+27.3%$37K+32.1%$12K-69.2%$41K-6.8%$87K+210.7%$34K-12.8%$49K-46.7%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$3.2M+14.5%$3.4M+12.4%$3.1M+12.9%$2.3M-11.3%$1.7M-44.8%$1.9M-31.3%$2.4M-6.4%$2.8M+27.8%
Current Liabilities$3.1M+16.7%$3.2M+14.7%$2.9M+15.4%$2.2M-7.9%$1.5M-46.0%$1.7M-30.7%$2.3M-3.5%$2.7M+37.2%
Non-Current Liabilities$128K-21.0%$149K-21.6%$191K-15.1%$133K-44.8%$137K-27.9%$140K-37.8%$160K-33.6%$162K-40.0%
Long-Term Debt$128K-4.5%$149K+10.4%$191K+40.4%$131K-4.4%$132K-2.2%$133K-2.2%$134K-2.2%$134K-2.9%
Total Equity$6.5M+3.9%$6.1M-16.9%$6.1M-22.3%$7.4M+1.4%$8.1M+9.7%$6.1M-22.9%$6.3M-13.5%$6.3M-30.9%
Retained Earnings-$132.3Mn/m-$130.2Mn/m-$127.3Mn/m-$124.9Mn/m-$122.8Mn/m-$122.3Mn/m-$120.7Mn/m-$119.6Mn/m

Not reported in any period shown, so not listed: Goodwill.

IGC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IGC quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KTQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-Q
Operating Cash Flow-$1.4Mn/m-$1.4Mn/m-$1.2Mn/m-$1.2Mn/m-$2.1Mn/m-$1.4Mn/m-$730Kn/m-$1.3Mn/m
Depreciation & Amortization$58K-63.1%$56K-61.4%$58K-64.2%$64K-61.0%$119K-17.9%$141K-13.0%$154K-6.1%$157K-1.9%
Stock-Based CompensationN/AN/A$4.0M-13.0%N/AN/A$4.7M+2.2%$455KN/A
Capital Expenditures$0-100.0%$5K-82.8%$1K-97.4%$12K-20.0%$29K0.0%$8K-78.9%$18K+20.0%$27K-60.3%
Free Cash Flow-$1.4Mn/m-$1.4Mn/m-$1.2Mn/m-$1.2Mn/m-$2.1Mn/m-$1.4Mn/m-$748Kn/m-$1.3Mn/m
Investing Cash Flow-$193Kn/m-$254Kn/m-$170Kn/m-$228Kn/m-$374Kn/m$580Kn/m-$142Kn/m-$104Kn/m
Financing Cash Flow$1.7M+383.8%$1.7M+117.9%$710K-71.7%$1.3M+89.5%$3.1M+291.7%$851K-66.1%$805K+20.7%$345Kn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

IGC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IGC quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KTQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-Q
Gross Margin18.6%-21.9pp18.1%-29.9pp17.3%-42.6ppN/A51.8%+3.8pp46.9%-13.0pp46.7%-11.3pp40.5%-24.7pp
Operating Margin-588.7%-1050.6%-775.4%N/A-1517.8%-580.8%-428.2%-730.7%
Net Margin-623.8%-1107.9%-757.7%N/A-953.4%-487.5%-363.0%-711.7%
Return on Equity-31.5%-2.2pp-47.9%-24.6pp-39.2%-9.1ppN/A-22.5%+0.8pp-26.3%+3.9pp-18.9%+20.5pp-29.2%+32.5pp
Return on Assets-21.0%-0.9pp-30.9%-14.4pp-26.2%-3.7ppN/A-18.7%-2.1pp-20.1%+2.3pp-13.7%+15.4pp-20.2%+29.5pp
Current Ratio0.42-0.7x0.39-1.1x0.40-1.4x0.83-0.8x1.32-0.2x1.25-0.5x1.28-0.3x1.15-0.7x
Debt-to-Equity0.020.0x0.020.0x0.030.0x0.020.0x0.020.0x0.020.0x0.020.0x0.020.0x
Liabilities-to-Equity0.500.0x0.55+0.1x0.50+0.2x0.310.0x0.20-0.2x0.310.0x0.380.0x0.45+0.2x
Asset Turnover0.030.0x0.030.0x0.030.0xN/A0.020.0x0.040.0x0.040.0x0.030.0x
FCF Margin-432.0%-511.3%-386.1%N/A-1109.4%-431.4%-226.7%-523.0%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
IGC Pharma, Inc. IGC FY2025 $1.3M -$7.1M N/A $19.6M 44/100
Celularity Inc. CELU FY2025 $26.6M -$91.7M N/A $15.2M 43/100
Atossa Therapeutics, Inc. ATOS FY2025 N/A -$34.8M N/A $15.9M —
Cel-Sci Corporation CVM FY2025 N/A -$25.4M N/A $21.3M —
TransCode Therapeutics, Inc. RNAZ FY2025 N/A -$34.7M N/A $20.1M —
BioStem Technologies, Inc. BSEM FY2025 $47.5M -$6.6M -13.9% $12.2M 69/100

Frequently Asked Questions

IGC Pharma, Inc. (IGC) reported $1.3M in total revenue for fiscal year 2025. This represents a -5.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

IGC Pharma, Inc. (IGC) revenue declined by 5.5% year-over-year, from $1.3M to $1.3M in fiscal year 2025.

No, IGC Pharma, Inc. (IGC) reported a net loss of $7.1M in fiscal year 2025.

IGC Pharma, Inc. (IGC) reported diluted earnings per share of -$0.09 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

IGC Pharma, Inc. (IGC) had EBITDA of -$6.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, IGC Pharma, Inc. (IGC) had $405K in cash and equivalents against $134K in long-term debt.

IGC Pharma, Inc. (IGC) had a gross margin of 48.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

IGC Pharma, Inc. (IGC) has a return on equity of -112.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

IGC Pharma, Inc. (IGC) recorded an outflow of $4.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

IGC Pharma, Inc. (IGC) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

IGC Pharma, Inc. (IGC) had $8.7M in total assets as of fiscal year 2025, including both current and long-term assets.

IGC Pharma, Inc. (IGC) invested $112K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

IGC Pharma, Inc. (IGC) invested $3.7M in research and development during fiscal year 2025.

IGC Pharma, Inc. (IGC) had 84M shares outstanding as of fiscal year 2025.

IGC Pharma, Inc. (IGC) had a current ratio of 1.28 as of fiscal year 2025, which is considered adequate.

IGC Pharma, Inc. (IGC) had a debt-to-equity ratio of 0.02 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

IGC Pharma, Inc. (IGC) had a liabilities-to-equity ratio of 0.38 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

IGC Pharma, Inc. (IGC) had a return on assets of -81.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

IGC Pharma, Inc. (IGC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $19.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

IGC Pharma, Inc. (IGC) trades at 15.4x sales, its market capitalization divided by $1.3M revenue, FY2025. The market capitalization is $19.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, IGC Pharma, Inc. (IGC) held $405K in cash, cash equivalents and investments, and reported an operating cash outflow of $4.8M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

IGC Pharma, Inc. (IGC) has an Altman Z-Score of -17.04, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

IGC Pharma, Inc. (IGC) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

IGC Pharma, Inc. (IGC) reported a net loss of $7.1M while operations used $4.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

IGC Pharma, Inc. (IGC) reported an operating loss of $7.4M against $5K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

IGC Pharma, Inc. (IGC) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top